Based on this, and because type I IFNs signal through the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway to induce IFN-stimulated gene expression, therapeutic inhibitors of the JAK/STAT pathway have appeared as potentially new drugs in SS and other type I IFN-mediated autoimmune diseases, and are currently in early-phase clinical trials (161, 162). Here, IFNA1 is linked to autoimmune disease.